On Tuesday, the House Committee on Oversight and Government Reform raised concerns in a letter to the Food and Drug Administration about a recent business maneuver made by the 32-year-old former hedge fund manager. Through a new business investment, KaloBios Pharmaceuticals, Shkreli had bought the rights to a drug for Chagas disease, a rare tropical parasitic ailment, earlier this month.
Read Full Article »
